Lonza
Kadri Qarri is a seasoned professional in the biotechnology field, currently serving as a Senior CQV Engineer Freelance at Lonza since January 2022. Prior to this role, Kadri worked as a CQV Engineer Freelance at Biogen from September 2019 to December 2021 and as a Consultant via Pharmatronic AG at Roche between September 2016 and August 2019, focusing on Quality Assurance, Validation, and Qualification activities in Basel Biotechnologie. Earlier experience includes a position as Manufacturing Associate DSP at Celonic AG from February 2015 to June 2016 and as a Chemical Technician DSP at Novartis from August 2008 to August 2009, specializing in Downstream Processing within Clinical Manufacturing and Biotechnology. Kadri holds a Bachelor of Science (B.Sc.) in Molecular Life Sciences from the University of Applied Sciences Northwestern Switzerland, along with a Technische Berufsmatura from Allgemeine Gewerbeschule Basel and an apprenticeship as a chemical technician from Novartis.
This person is not in any teams
This person is not in any offices
Lonza
68 followers
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a range of products for applications in nutrition, hygiene, preservation, water treatment, materials protection, and other industrial markets. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics.